

Subject	Diagnosis	Histology	Stage at study entry	PD-L1 TC % positivity at baseline*
MET-B-001	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	0
MET-B-002	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	0
MET-B-004	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	0
MET-B-005	ER+/HER2- BC	Inflammatory Carcinoma	IV	0
MET-B-008	ER+/HER2- BC	Invasive Lobular Carcinoma	IV	0
MET-B-009	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	0
MET-B-010	ER+/HER2- BC	Invasive Lobular Carcinoma	IV	10
MET-B-011	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	0
MET-B-012	ER+/HER2- BC	Invasive Ductal Carcinoma	IV	10
MET-C-002	MSS-CRC	Mucinous adenocarcinoma	IVB	0
MET-C-005	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-008	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-009	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-010	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-011	MSS-CRC	Adenocarcinoma	IVA	0
MET-C-013	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-014	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-015	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-016	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-019	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-020	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-021	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-022	MSS-CRC	Adenocarcinoma	IVB	0
MET-C-023	MSS-CRC	Adenocarcinoma	IVB	0
MET-O-001	PR-OC	High grade serous carcinoma	IVB	0
MET-O-002	PR-OC	High grade serous carcinoma	IVB	0
MET-O-004	PR-OC	High grade serous carcinoma	IVB	0
MET-O-005	PR-OC	High grade serous carcinoma	IVB	0

### Supplementary Table 1. Patient Histology Information

Programmed death ligand 1 (PD-L1); tumor cell (TC); estrogen receptor positive, HER2 negative breast cancer (ER+HER2- BC); microsatellite stable colorectal cancer (MSS-CRC); platinum resistant ovarian cancer (PR-OC).

\*PD-L1 expression in tumor cells was assessed by immunohistochemistry using VENTANA SP263 assay (Roche Diagnostics), with positivity defined as staining in tumor cells  $\geq 25\%$ .

